Here are the Form 4 insider transactions from Quest Diagnostics Inc. (DGX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics CEO and President J. E. Davis reported mixed equity transactions involving company stock. On a grant date of March 4, 2026, Davis acquired 51,652 shares of Quest Diagnostics common stock at a price of $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). In a related move, 26,414 shares of common stock were disposed of back to the issuer at $204.86 per share to cover tax withholding obligations from the settlement. After these transactions, Davis directly held 142,423 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president for Diagnostic Services Patrick Plewman reported a mix of stock award activity, tax-related share disposition, and an open-market sale of common stock. On March 4, he acquired 5,682 shares as a grant or award at $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). On the same date, 2,827 shares were disposed of at $204.86 per share to Quest Diagnostics to cover tax withholding obligations from that award, leaving 18,053 shares directly owned afterward. On March 5, he sold 2,855 shares of common stock in an open-market transaction at $206.21 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 15,198 shares.
Quest Diagnostics executive Michael J. Deppe reported offsetting equity transactions involving company stock. He acquired 1,473 shares of Quest Diagnostics common stock on a grant/award basis tied to a performance stock award, valued at $204.86 per share, increasing his holdings at that moment to 35,946 shares.
On the same date, 750 shares were disposed of back to Quest Diagnostics at $204.86 per share solely to cover tax withholding obligations arising from the settlement of that performance stock award. After the tax-withholding disposition, Deppe directly owned 35,196 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy reported a mix of equity award activity and related share disposition. He acquired 6,200 shares of common stock on March 4, 2026 as stock issued in settlement of a performance stock award approved under Rule 16b-3(d). To cover tax withholding from this award, 2,628 shares of common stock at $204.86 per share were disposed of back to the issuer. After these transactions, he held 13,441 shares directly, plus additional indirect holdings of 358 shares by trust and 1,658 shares in a 401(k) plan, based on information from the plan administrator.
Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock. On March 3, 2026, she executed an open-market sale of 632 shares of common stock at $207.73 per share, leaving 67,122 shares held directly.
On March 2, 2026, 648 shares were disposed of at $204.86 per share to cover tax obligations tied to the vesting of restricted share units, and the sale activity was carried out under a pre-arranged Rule 10b5-1 trading plan. She also holds 4,502 shares indirectly through a company 401(k)/profit sharing plan.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported a Form 4 transaction involving common stock. On the reported date, he disposed of 869 shares at $204.86 per share in a tax-withholding transaction tied to the vesting of a prior restricted stock unit grant. This was a sale of shares to satisfy tax obligations rather than an open-market trade. After this transaction, he directly owned 27,041 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president and general counsel Michael E. Prevoznik reported recent stock transactions. On March 3, he executed an open-market sale of 526 shares of common stock at $207.73 per share under a Rule 10b5-1 sales plan, leaving 37,557 shares held directly afterward. On March 2, 288 shares were disposed of at $204.86 per share to cover tax obligations from the vesting of restricted share units. He also has 5,737 shares held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported two stock transactions in company common stock. He disposed of 2,968 shares at $204.86 per share to satisfy tax obligations from the vesting of a prior restricted share unit grant. He also completed an open-market sale of 10,000 shares at $212.52 per share under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 117,185 Quest Diagnostics shares.
Quest Diagnostics senior vice president Patrick Plewman reported two stock dispositions. He sold 410 shares of common stock in an open-market transaction at $207.73 per share under a Rule 10b5-1 sales plan he previously adopted.
He also disposed of 230 shares at $204.86 per share to cover tax obligations from the vesting of an earlier restricted share unit grant. After these transactions, he directly owns 15,198 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy disposed of 205 shares of common stock at $204.86 per share to cover tax obligations from vesting restricted share units. This tax-withholding transaction on March 2, 2026 was not an open-market sale. After the transaction, he held 9,869 shares directly, plus additional indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported a small, automatic share disposition related to taxes. On the transaction date, 188 shares of common stock were withheld at a price of $204.86 per share to satisfy tax obligations from vesting restricted share units. After this tax-withholding event, Delaney directly owned 8,508 Quest Diagnostics common shares.
Quest Diagnostics senior executive reports small tax-related share disposition. Michael J. Deppe, SVP, Corporate Controller and Chief Accounting Officer of Quest Diagnostics, had 88 shares of common stock withheld at $204.86 per share on a Form 4 event dated March 2, 2026 to satisfy tax obligations from previously vested restricted share units, rather than an open-market sale. After this transaction, he directly held 34,473 shares of Quest Diagnostics common stock. The filing also notes indirect ownership of 706 shares through the company’s 401(k) Profit Sharing Plan, with balances based on plan administrator data.
Quest Diagnostics senior vice president Patrick Plewman reported a mix of stock transactions and equity awards. On February 19, 2026, he completed an open‑market sale of 958 shares of common stock, leaving him with 15,838 shares held directly.
On February 18, 2026, he received a grant of 9,009 non-qualified stock options, which vest in three equal annual installments starting on the first anniversary of the grant date. He was also awarded 1,952 restricted stock units.
That same day, a total of 537 shares of common stock (244 shares at one price and 293 shares at another) were surrendered to the issuer solely to cover tax withholding obligations from vesting restricted stock units. The footnotes state the 958‑share sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted by Plewman.
Quest Diagnostics Executive Vice President and CFO Sam Sam reported several equity-related transactions. On February 18, 2026, he received a grant of 18,303 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also acquired 3,965 shares of common stock as an award of restricted stock units and disposed of 855 and 1,010 shares of common stock solely to cover tax withholding obligations arising from the vesting of restricted stock units, at prices of $210.01 and $206.99 per share. In addition, on January 28, 2026, he acquired 69 shares of common stock through a dividend reinvestment plan at $183.514 per share. Following these transactions, his directly held common stock position was reported as 27,841 shares, and he directly held 18,303 options.
Quest Diagnostics SVP & General Counsel Michael E. Prevoznik reported a mix of stock transactions. On February 19, 2026, he sold 1,111 shares of common stock in an open-market transaction at $204.83 per share, executed under a Rule 10b5-1 sales plan.
On February 18, 2026, he received a grant of 9,289 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant. He also acquired 2,013 shares of common stock as an award of restricted stock units, while 301 shares at $210.01 and 347 shares at $206.99 of common stock were surrendered to cover tax withholding from vesting. In addition, 5,738 shares are held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported equity compensation and related tax withholding transactions. Davis was granted 73,225 non-qualified stock options, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also received 15,857 shares of common stock, representing an award of restricted stock units. To cover tax withholding obligations arising from the vesting of restricted stock units, 2,396 shares and 3,788 shares of common stock were disposed of back to the issuer at prices of $210.01 and $206.99 per share, respectively. After these transactions, Davis directly owned 130,153 shares of common stock and 73,225 stock options.
Quest Diagnostics executive Catherine T. Doherty, EVP, Regional Businesses, reported multiple equity transactions. On February 19, 2026, she completed an open-market sale of 1,433 shares of common stock at $204.83 per share under a Rule 10b5-1 sales plan, leaving 68,402 directly held shares.
On February 18, 2026, she received a grant of 13,514 non-qualified stock options at an exercise price of $0.00 per option, vesting in three equal annual installments beginning on the first anniversary of the grant date. She also acquired 2,928 shares of common stock as a restricted stock unit award, with related tax-withholding dispositions of 433 shares at $210.01 and 728 shares at $206.99. In addition, 4,503 shares are held indirectly through the company’s 401(k) and Supplemental Deferred Compensation Plan.
Quest Diagnostics senior vice president Karthik Kuppusamy reported multiple equity-related transactions. He received a grant of 9,853 non-qualified stock options and an award of 2,135 restricted stock units, both at no cost. Shares of common stock totaling 252 and 259 were disposed of to the issuer solely to cover tax withholding obligations from vesting restricted stock units. He also recorded a small acquisition of 16 common shares under Rule 16a-6 and reported indirect holdings through a 401(k) plan and a trust. The granted options vest in three equal annual installments beginning on the first anniversary of the grant date.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported multiple equity-related transactions. On February 18, 2026, he was granted a non-qualified stock option for 7,332 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date. He also received 1,586 shares of common stock, which the footnotes describe as an award of restricted stock units. On the same date, 205 shares at $210.01 and 230 shares at $206.99 of common stock were disposed of back to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Separately, on January 28, 2026, he acquired 15 shares of common stock through a dividend reinvestment plan, which the rules allow to be reported later on Form 5 but he chose to report on this Form 4.
Quest Diagnostics SVP and Chief Accounting Officer Michael J. Deppe reported a mix of equity grants and related tax share withholdings. On February 18, 2026, he was granted a non‑qualified stock option covering 1,688 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date.
He also received an award of 366 restricted stock units. To cover tax withholding from vesting RSUs, 83 shares of common stock at $210.01 and 99 shares at $206.99 were disposed of to the issuer. After these transactions, he directly owns 34,560 shares of common stock and holds 1,688 options, plus an additional 706 shares indirectly through the company’s 401(k) plan.
Quest Diagnostics director Wright Lassiter III reported acquiring 7 shares of common stock on January 28, 2026 at $183.51 per share. The filing states these shares were obtained through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, but were reported early on Form 4. Following this small acquisition, his directly held position increased to 9,057 shares, a figure that includes shares previously acquired via dividend reinvestment since his last Form 4 filing.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.
Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.
Quest Diagnostics EVP Catherine T. Doherty reported an option exercise and related share sales. On 02/13/2026 she exercised 26,165 non-qualified stock options at $112.17 per share, receiving the same number of common shares.
That day she sold 26,165 common shares in several open-market transactions at weighted average prices between $205.2072 and $209.1024, under a pre-established Rule 10b5-1 sales plan. After these transactions, she held 68,068 common shares directly and 4,503 shares indirectly through a 401(k)/deferred compensation plan.
Quest Diagnostics executive Patrick Plewman reported multiple stock transactions involving DGX shares. On January 28, 2026, he acquired 48 shares of common stock at $183.512 per share through a dividend reinvestment plan administered by his broker, bringing direct ownership to 15,381 shares.
On February 10, 2026, he exercised a non-qualified stock option for 5,662 shares of common stock at an exercise price of $121.805 per share and immediately sold 5,662 shares of common stock at $204 per share in an open-market transaction. After these transactions, he directly owned 15,381 shares of Quest Diagnostics common stock. The filing notes that the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan.
Quest Diagnostics CEO and President James E. Davis reported an option exercise and related stock sales. On 11/25/2025, he exercised a non-qualified stock option to buy 55,093 shares of common stock at an exercise price of $95.795 per share, increasing his direct holdings to 175,573 shares immediately after the exercise.
That same day, he sold shares in several market transactions under a pre-arranged Rule 10b5-1 sales plan. These sales included 9,342 shares at a weighted average price of $191.5888, 41,004 shares at $192.2715, and 4,747 shares at $192.9717, each executed in multiple trades within disclosed price ranges. After these transactions, Davis directly owned 120,480 shares of Quest Diagnostics common stock, and the reported stock option grant showed 0 options remaining following the exercise.
Quest Diagnostics director reports small stock sale
A director of Quest Diagnostics Inc. reported selling 1,250 shares of common stock on 11/25/2025 at a price of $191.76 per share. This insider now directly owns 17,037 Quest Diagnostics shares after the transaction. The filing is a Form 4 submitted for board member Vicky B. Gregg, with the form signed by an attorney-in-fact.
Quest Diagnostics senior executive Mark E. Delaney, SVP & Chief Commercial Officer, reported stock option exercises and a share sale in Quest Diagnostics Inc. common stock. On 11/18/2025, he exercised 7,846 stock options at an exercise price of $144.47 per share and 100 stock options at $143.33 per share, acquiring the same number of Quest Diagnostics shares. On the same date, he sold 7,946 shares of common stock at a price of $187.35 per share. Following these transactions, he directly owned 7,530 shares of Quest Diagnostics common stock. The filing notes that the exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person.